After first clinical evidence of CAR T-cell activity in neuroblastoma [13, 14, 40], clinical studies using CAR T cells directed against CD19 have demonstrated the impressive therapeutic potential of CAR modified T cells in patients [24–27, 30, 41]. The gene discussed is CD19; the disease is neuroblastoma.